LLY

916.49

-1.52%↓

JNJ

237.15

-0.37%↓

ABBV

208.28

-5.27%↓

NVS

149.76

-3.06%↓

AZN

188.42

-1.47%↓

LLY

916.49

-1.52%↓

JNJ

237.15

-0.37%↓

ABBV

208.28

-5.27%↓

NVS

149.76

-3.06%↓

AZN

188.42

-1.47%↓

LLY

916.49

-1.52%↓

JNJ

237.15

-0.37%↓

ABBV

208.28

-5.27%↓

NVS

149.76

-3.06%↓

AZN

188.42

-1.47%↓

LLY

916.49

-1.52%↓

JNJ

237.15

-0.37%↓

ABBV

208.28

-5.27%↓

NVS

149.76

-3.06%↓

AZN

188.42

-1.47%↓

LLY

916.49

-1.52%↓

JNJ

237.15

-0.37%↓

ABBV

208.28

-5.27%↓

NVS

149.76

-3.06%↓

AZN

188.42

-1.47%↓

Inicio・Lista de Acciones・Veracyte Inc

Veracyte Inc

Cerrado

SectorSalud

33.18 -0.93

Comprar Vender

Resumen

Variación precio

24h

Actual

Mínimo

32.82

Máximo

33.56

Métricas clave
By Trading Economics
Ingresos	30M 49M
Ventas	8.8M 141M
P/B Media del Sector	40.146 57.833
Margen de beneficio	34.967
Empleados	755
EBITDA	22M 46M

Recomendaciones
By TipRanks
Recomendaciones	Comprar
Estimación a 12 meses	+32.92% upside

Dividendos
By Dow Jones
Próximas Ganancias	6 may 2026

Estadísticas de Mercado
By TradingEconomics
Capitalización de Mercado	-210M 2.6B
Apertura anterior	34.11
Cierre anterior	33.18

Noticias sobre sentimiento de mercado

By Acuity

89%

11%

331 / 351 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Weak Bearish Evidence

30.5 / 31.38 Soporte y Resistencia

Veracyte Inc Gráfico

El rendimiento pasado no es un indicador fiable de resultados futuros.

Noticias Relacionadas

18 mar 2026, 22:51 UTC

Ganancias

AIA Group Value of New Business Rose in 2025, Plans $1.7 Billion New Share Buyback

18 mar 2026, 21:40 UTC

Adquisiciones, fusiones, absorciones

Constellation Energy to Sell Portfolio of Assets for $5 Billion to Satisfy Regulators

18 mar 2026, 20:31 UTC

Ganancias

Micron 2Q Sales Nearly Triple Amid Tight Memory Supply

18 mar 2026, 23:49 UTC

Charlas de Mercado

Noticias de Eventos Importantes

Nikkei May Fall on Renewed Concerns About Higher Energy Prices -- Market Talk

18 mar 2026, 23:31 UTC

Charlas de Mercado

Gold Rises on Likely Technical Recovery -- Market Talk

18 mar 2026, 22:49 UTC

Charlas de Mercado

New Zealand's Economic Recovery Has Yet to Find Footing -- Market Talk

18 mar 2026, 22:41 UTC

Charlas de Mercado

Woodside Energy Opts for 'Safe, Experienced' Choice as CEO -- Market Talk

18 mar 2026, 22:36 UTC

Ganancias

AIA Group Value of New Business Rose in 2025, Plans $1.7B New Share Buyback

18 mar 2026, 22:24 UTC

Ganancias

AIA Group Announces New Share Buyback of $1.7B >1299.HK

18 mar 2026, 22:23 UTC

Ganancias

AIA Group 2025 Value of New Business Margin Was 58.5%, Up 3.6 Ppt on Year >1299.HK

18 mar 2026, 22:23 UTC

Ganancias

AIA Group 2025 Value of New Business $5.52B Vs. $4.71B >1299.HK

18 mar 2026, 21:58 UTC

Ganancias

Micron Sales Nearly Triple Amid Tight Memory Supply -- Update

18 mar 2026, 21:55 UTC

Charlas de Mercado

Ganancias

Global Equities Roundup: Market Talk

18 mar 2026, 21:55 UTC

Charlas de Mercado

Ganancias

Micron's Phone, PC Business Could Shrink Due to Memory Shortage -- Market Talk

18 mar 2026, 21:40 UTC

Charlas de Mercado

Fuel Price Rise Equates to 20 Bps Rate Hike on Australian Households -- Market Talk

18 mar 2026, 21:16 UTC

Charlas de Mercado

More Procter & Gamble Alumni Join Strobel at Coty -- Market Talk

18 mar 2026, 21:00 UTC

Noticias de Eventos Importantes

Iran War Puts Pressure on Japan's Economy. Takaichi Is In a Bind. -- Barrons.com

18 mar 2026, 20:58 UTC

Ganancias

Micron 2Q Gross Margin Nearly Doubled Due to Higher Pricing, CFO Says

18 mar 2026, 20:41 UTC

Ganancias

Micron Reports Extraordinary Earnings. Its Growth Is Accelerating. -- Barrons.com

18 mar 2026, 20:29 UTC

Ganancias

Micron Reports Extraordinary Earnings. Its Growth Is Accelerating. -- Barrons.com

18 mar 2026, 20:25 UTC

Ganancias

Micron Reports Extraordinary Earnings. Its Growth Is Accelerating. -- Barrons.com

18 mar 2026, 20:17 UTC

Ganancias

These Stocks Are Today's Movers: Micron, Swarmer, Lumentum, Trade Desk, Macy's, Williams-Sonoma, and More -- Barrons.com

18 mar 2026, 20:14 UTC

Charlas de Mercado

Airlines Can't Offset Higher Fuel Prices for Long -- Market Talk

18 mar 2026, 20:09 UTC

Ganancias

Micron Reports Extraordinary Earnings. The Stock Is Up. -- Barrons.com

18 mar 2026, 20:07 UTC

Ganancias

Micron Technology Raises Qtr Dividend to 15c Vs. 11.5c >MU

18 mar 2026, 20:06 UTC

Ganancias

Micron Technology Board Has Approved 30% Increase in Qtrly Div >MU

18 mar 2026, 20:04 UTC

Ganancias

Micron Technology 2Q Operating Cash Flow $11.9 B >MU

18 mar 2026, 20:04 UTC

Ganancias

Micron Technology Sees 3Q Operating Expenses About $1.6 B >MU

18 mar 2026, 20:04 UTC

Ganancias

Micron Technology Sees 3Q Gross Margin About 81% >MU

18 mar 2026, 20:03 UTC

Ganancias

Micron Technology Sees 3Q Adj EPS $19.15 +/- 40c >MU

Comparación entre iguales

Cambio de precio

Veracyte Inc Esperado

Precio Objetivo

By TipRanks

32.92% repunte

Estimación a 12 meses

Media 44.5 USD 32.92%

Máximo 50 USD

Mínimo 37 USD

De acuerdo con 6 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Veracyte Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Comprar

6 ratings

Comprar

Mantener

Vender

De acuerdo con 6 analistas que ofrecen calificaciones bursátiles a para Veracyte Inc Dist en los últimos 3 meses.

Puntuación técnica

By Trading Central

30.5 / 31.38Soporte y Resistencia

Recent bearish events outweigh bullish events.

Bearish events outweigh bullish events.

Recent bearish events outweigh bullish events.

Sentimiento

By Acuity

331 / 351 Clasificación en Salud

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

Acerca de Veracyte Inc

Veracyte, Inc. operates as a diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier for cancerous thyroid nodules; Decipher Prostate Biopsy and Radical Prostatectomy for prostate cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; Percepta Nasal Swab Test for lung cancer diagnosis; and Envisia Genomic Classifier for diagnosing interstitial lung disease, including idiopathic pulmonary fibrosis. It is also developing Envisia Classifier, the nCounter analysis system; and LymphMark for lymphoma subtyping test. The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California.